NEW YORK, Dec. 12 — MDS Pharma Services and Iconix Pharmaceuticals announced Wednesday an agreement to develop a new system to evaluate drug efficacy and toxicity. The system, called DrugMatrix, will combine chemical, genomic, and pharmacological information to allow for rapid profiling of drug candidates. Incyte, which entered an agreement with and made an equity investment in Iconix in May 2001, will commercialize the new platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.